Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

Now that Cour has demonstrated clinical proof of concept, Takeda has exercised its option to license the company’s first-in-class celiac disease therapy that induces tolerance.

On Tuesday at the United European Gastroenterology Week meeting in Barcelona, Cour Pharmaceutical Development Co. Inc.

Read the full 406 word article

User Sign In